Notice of AGM & Annual Report
Summary by AI BETAClose X
Publication of Notice of Annual General Meeting and Annual Report
Dublin, London | 1 April 2026: Uniphar plc (the "Company" or "Uniphar") wishes to announce that it is today posting to shareholders its Notice of Annual General Meeting ("AGM") for 2026 together with its annual report and accounts for the year ended 31 December 2025 ("Annual Report"). The AGM will be held at 11.00 a.m. on 7 May 2026 at the offices of William Fry LLP, 2 Grand Canal Square, Dublin 2, D02 A342.
Uniphar values the participation of its shareholders at its AGM and encourages all shareholders to take part in the meeting either in person or by voting and raising questions in advance.
The Notice of Meeting, Form of Proxy and Annual Report are available to view on the Company's website at https://www.uniphar.ie/static/investors/shareholder-centre/AGM/AGM-2026 and will be available for inspection during normal business hours on any business day from today until the conclusion of the AGM at the registered office of the Company.
Proxy voting can be carried out in advance of the AGM. Details of how to do so are set out in further detail in the Notice of Meeting.
A conference call facility will be provided to allow shareholders to listen live to the business of the AGM. Please note that you will not be able to use this facility to vote, raise points or issues or ask questions. If you wish to listen live to the AGM proceedings, you can register for the conference call and receive participant log-in details at https://www.uniphar.ie/static/investors/shareholder-centre/AGM/AGM-2026 Shareholders availing of this facility should ensure to submit any votes in advance of the meeting as it will not be possible to vote using the conference call facility.
Shareholders are invited to submit questions in writing in advance of the meeting either by email to companysecretary@uniphar.ie or by post to the Company Secretary, Uniphar plc, 4045 Kingswood Road, Citywest Business Park, Co. Dublin, D24 V06K, Ireland. Questions must be received by 5 p.m. on 5 May 2026. Shareholders must include their Shareholder Reference Number (as set out on their Form of Proxy) with any question submitted.
Contact details
|
Uniphar Group
|
Tel: +353 (0) 1 428 7777 |
|
Allan Smylie, Head of Strategy and IR |
|
|
|
|
|
Davy (Joint Corporate Broker, Nominated Advisor and Euronext Growth Listing Sponsor)
|
Tel: +353 (0) 1 679 6363 |
|
Daragh O'Reilly Niall Gilchrist Ivan Murphy |
|
|
|
|
|
RBC Capital Markets (Joint Corporate Broker)
|
Tel: +44 (0) 20 7653 4000 |
|
Jamil Miah Daniel Saveski |
|
|
|
|
|
Stifel Nicolaus Europe Limited (Joint Corporate Broker)
|
Tel: +44 (0) 20 7710 7600 |
|
Matt Blawat Ben Maddison Francis North |
|
|
|
|
|
Q4 PR
|
Tel: +353 (0) 1 475 1444 |
|
Iarla Mongey, Public Relations Advisor to Uniphar Group |
|
About Uniphar plc
Headquartered in Dublin, Ireland, the Uniphar Group is an international diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions - Uniphar Pharma, Uniphar Medtech and Uniphar Supply Chain & Retail. The Group is active in Europe, North America, APAC and MENA and delivers to 160+ countries.
The Company's vision is to improve patient access to pharmaco-medical products and treatments by enhancing connectivity between manufacturers and healthcare stakeholders. Uniphar represents a strong combination of scale, growth, and profitability.
Uniphar Supply Chain & Retail
Uniphar Supply Chain & Retail is the leading pharmaceutical wholesaler in Ireland with a growing symbol group offering of retail pharmacies. The Group's strategy for Uniphar Supply Chain & Retail is to grow our wholesale market share, our symbol group network and our own brand, in-licenced and consumer products portfolio.
Uniphar Medtech
Uniphar Medtech is a leading Pan-European medical device distributor and solutions partner. The Group's strategy for Uniphar Medtech is to grow our service offering across Europe and expand our addressable market by serving new specialities and new manufacturers.
Uniphar Pharma
Uniphar Pharma operates a global business with high value services across the lifecycle of a pharmaceutical product. We enable pharma and biotech companies to bring innovative medicines to global markets and provide healthcare professionals with access to medicines they can't source through traditional channels. Our strategy is to build a leading platform to provide the specialist support and expertise needed to improve access to these medicines.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 3 hours ago Abenójar Tungsten, S.A
- 4 hours ago SpaceandPeople
- 4 hours ago Schroder Income Growth Fund
- 5 hours ago Trainline
- 5 hours ago Coca-Cola Europacific Partners (DI)